Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lanreotide contro placebo prima dell'intervento per prevenire una complicazione chirurgica chiamata fistola pancreatica

4 novembre 2026 aggiornato da: SWOG Cancer Research Network

Uno studio randomizzato di fase III in cieco di lanreotide per la prevenzione della fistola pancreatica postoperatoria

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.

SECONDARY OBJECTIVES:

I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.

II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.

ADDITIONAL OBJECTIVES:

I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.

II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.

BANKING OBJECTIVE:

I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

Tipo di studio

Interventistico

Iscrizione (Stimato)

274

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Sospeso
        • University of Alabama at Birmingham Cancer Center
      • Daphne, Alabama, Stati Uniti, 36526
        • Sospeso
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Stati Uniti, 36532
        • Sospeso
        • Thomas Hospital
      • Mobile, Alabama, Stati Uniti, 36607
        • Sospeso
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Stati Uniti, 36571
        • Sospeso
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Gilbert, Arizona, Stati Uniti, 85234
        • Sospeso
        • Banner MD Anderson Cancer Center
    • California
      • Duarte, California, Stati Uniti, 91010
        • Sospeso
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, Stati Uniti, 92093
        • Reclutamento
        • UC San Diego Moores Cancer Center
        • Contatto:
        • Investigatore principale:
          • Andrew M. Lowy
      • Loma Linda, California, Stati Uniti, 92357
        • Sospeso
        • Veterans Affairs Loma Linda Healthcare System
      • Los Angeles, California, Stati Uniti, 90033
        • Sospeso
        • USC / Norris Comprehensive Cancer Center
      • San Diego, California, Stati Uniti, 92103
        • Sospeso
        • UC San Diego Medical Center - Hillcrest
    • Delaware
      • Newark, Delaware, Stati Uniti, 19718
        • Sospeso
        • Christiana Care Health System-Christiana Hospital
      • Newark, Delaware, Stati Uniti, 19713
        • Sospeso
        • Helen F Graham Cancer Center
      • Newark, Delaware, Stati Uniti, 19713
        • Sospeso
        • Medical Oncology Hematology Consultants PA
      • Wilmington, Delaware, Stati Uniti, 19801
        • Sospeso
        • Christiana Care Health System-Wilmington Hospital
    • Florida
      • Ruskin, Florida, Stati Uniti, 33570
        • Sospeso
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Stati Uniti, 33612
        • Reclutamento
        • Moffitt Cancer Center - McKinley Campus
        • Contatto:
        • Investigatore principale:
          • Andrew J. Sinnamon
      • Tampa, Florida, Stati Uniti, 33607
        • Sospeso
        • Moffitt Cancer Center-International Plaza
      • Tampa, Florida, Stati Uniti, 33612
        • Sospeso
        • Moffitt Cancer Center
      • Wesley Chapel, Florida, Stati Uniti, 33544
        • Sospeso
        • Moffitt Cancer Center at Wesley Chapel
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Sospeso
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Stati Uniti, 30308
        • Sospeso
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Stati Uniti, 30322
        • Sospeso
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Stati Uniti, 30303
        • Sospeso
        • Grady Health System
      • Johns Creek, Georgia, Stati Uniti, 30097
        • Sospeso
        • Emory Johns Creek Hospital
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
        • Contatto:
        • Investigatore principale:
          • Akhil Chawla
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • University of Illinois
        • Investigatore principale:
          • Aslam Ejaz
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 312-355-3046
      • Geneva, Illinois, Stati Uniti, 60134
        • Sospeso
        • Northwestern Medicine Cancer Center Delnor
      • Oak Brook, Illinois, Stati Uniti, 60523
        • Sospeso
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Stati Uniti, 60462
        • Sospeso
        • Northwestern Medicine Orland Park
      • Warrenville, Illinois, Stati Uniti, 60555
        • Sospeso
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Sospeso
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky/Markey Cancer Center
        • Investigatore principale:
          • Michael J. Cavnar
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 859-257-3379
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Sospeso
        • University Medical Center New Orleans
    • Maryland
      • Elkton, Maryland, Stati Uniti, 21921
        • Sospeso
        • Christiana Care - Union Hospital
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Sospeso
        • University of Michigan Rogel Cancer Center
      • Battle Creek, Michigan, Stati Uniti, 49017
        • Sospeso
        • Bronson Battle Creek
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Sospeso
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Sospeso
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Sospeso
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Muskegon, Michigan, Stati Uniti, 49444
        • Sospeso
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Stati Uniti, 49120
        • Sospeso
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Stati Uniti, 49444
        • Sospeso
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Stati Uniti, 49677
        • Sospeso
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Sospeso
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Sospeso
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Wyoming, Michigan, Stati Uniti, 49519
        • Sospeso
        • University of Michigan Health - West
    • Minnesota
      • Aitkin, Minnesota, Stati Uniti, 56431
        • Sospeso
        • Riverwood Healthcare Center
      • Baxter, Minnesota, Stati Uniti, 56425
        • Sospeso
        • Essentia Health - Baxter Clinic
      • Brainerd, Minnesota, Stati Uniti, 56401
        • Sospeso
        • Essentia Health Saint Joseph's Medical Center
      • Crosslake, Minnesota, Stati Uniti, 56442
        • Sospeso
        • Essentia Health - Saint Joseph's Crosslake Clinic
      • Deer River, Minnesota, Stati Uniti, 56636
        • Sospeso
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Stati Uniti, 56501
        • Sospeso
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Stati Uniti, 55805
        • Sospeso
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Stati Uniti, 55805
        • Sospeso
        • Miller-Dwan Hospital
      • Duluth, Minnesota, Stati Uniti, 55805
        • Sospeso
        • Essentia Health Cancer Center
      • Ely, Minnesota, Stati Uniti, 55731
        • Sospeso
        • Essentia Health - Ely Clinic
      • Fosston, Minnesota, Stati Uniti, 56542
        • Sospeso
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Stati Uniti, 55746
        • Sospeso
        • Essentia Health Hibbing Clinic
      • International Falls, Minnesota, Stati Uniti, 56649
        • Sospeso
        • Essentia Health - International Falls Clinic
      • Moose Lake, Minnesota, Stati Uniti, 55767
        • Sospeso
        • Essentia Health - Moose Lake Clinic
      • Park Rapids, Minnesota, Stati Uniti, 56470
        • Sospeso
        • Essentia Health - Park Rapids
      • Pequot Lakes, Minnesota, Stati Uniti, 56472
        • Sospeso
        • Essentia Health - Saint Joseph's Pequot Lakes Clinic
      • Pine River, Minnesota, Stati Uniti, 56474
        • Sospeso
        • Essentia Health - Saint Joseph's Pine River Clinic
      • Sandstone, Minnesota, Stati Uniti, 55072
        • Sospeso
        • Essentia Health Sandstone
      • Staples, Minnesota, Stati Uniti, 56479
        • Sospeso
        • Essentia Health - Saint Joseph's Staples Clinic
      • Virginia, Minnesota, Stati Uniti, 55792
        • Sospeso
        • Essentia Health Virginia Clinic
    • Missouri
      • Farmington, Missouri, Stati Uniti, 63640
        • Reclutamento
        • Parkland Health Center - Farmington
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • Sainte Genevieve, Missouri, Stati Uniti, 63670
        • Reclutamento
        • Sainte Genevieve County Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • St Louis, Missouri, Stati Uniti, 63131
        • Reclutamento
        • Missouri Baptist Medical Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • Sullivan, Missouri, Stati Uniti, 63080
        • Reclutamento
        • Missouri Baptist Sullivan Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • Sunset Hills, Missouri, Stati Uniti, 63127
        • Reclutamento
        • BJC Outpatient Center at Sunset Hills
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Sospeso
        • University of Nebraska Medical Center
    • Nevada
      • Reno, Nevada, Stati Uniti, 89502
        • Sospeso
        • Renown Regional Medical Center
    • New Jersey
      • Livingston, New Jersey, Stati Uniti, 07039
        • Sospeso
        • Saint Barnabas Medical Center
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Sospeso
        • Rutgers Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • Sospeso
        • University of New Mexico Cancer Center
    • New York
      • Rochester, New York, Stati Uniti, 14642
        • Sospeso
        • University of Rochester
      • Syracuse, New York, Stati Uniti, 13210
        • Sospeso
        • State University of New York Upstate Medical University
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Sospeso
        • Carolinas Medical Center/Levine Cancer Institute
      • Concord, North Carolina, Stati Uniti, 28025
        • Sospeso
        • Atrium Health Cabarrus/LCI-Concord
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58103
        • Sospeso
        • Essentia Health Cancer Center-South University Clinic
      • Fargo, North Dakota, Stati Uniti, 58122
        • Sospeso
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Stati Uniti, 58122
        • Sospeso
        • Sanford Broadway Medical Center
      • Jamestown, North Dakota, Stati Uniti, 58401
        • Sospeso
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
        • Sospeso
        • University of Cincinnati Cancer Center-UC Medical Center
      • Columbus, Ohio, Stati Uniti, 43210
        • Sospeso
        • Ohio State University Comprehensive Cancer Center
      • West Chester, Ohio, Stati Uniti, 45069
        • Sospeso
        • University of Cincinnati Cancer Center-West Chester
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18104
        • Reclutamento
        • Saint Luke's Cancer Center - Allentown
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 610-776-4714
        • Investigatore principale:
          • Darius C. Desai
      • Bethlehem, Pennsylvania, Stati Uniti, 18015
        • Reclutamento
        • Saint Luke's University Hospital-Bethlehem Campus
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 484-503-4151
        • Investigatore principale:
          • Darius C. Desai
      • Chadds Ford, Pennsylvania, Stati Uniti, 19317
        • Sospeso
        • Christiana Care Health System-Concord Health Center
      • Easton, Pennsylvania, Stati Uniti, 18045
        • Reclutamento
        • Saint Luke's Hospital-Anderson Campus
        • Contatto:
        • Investigatore principale:
          • Darius C. Desai
      • Quakertown, Pennsylvania, Stati Uniti, 18951
        • Reclutamento
        • Saint Luke's Hospital - Upper Bucks Campus
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 610-776-4714
        • Investigatore principale:
          • Darius C. Desai
      • Stroudsburg, Pennsylvania, Stati Uniti, 18360
        • Reclutamento
        • Saint Luke's Hospital - Monroe Campus
        • Contatto:
        • Investigatore principale:
          • Darius C. Desai
      • Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
        • Sospeso
        • Geisinger Wyoming Valley/Henry Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57104
        • Sospeso
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Stati Uniti, 57117-5134
        • Sospeso
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Knoxville, Tennessee, Stati Uniti, 37920
        • Sospeso
        • University of Tennessee - Knoxville
      • Memphis, Tennessee, Stati Uniti, 38120
        • Sospeso
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05405
        • Sospeso
        • University of Vermont and State Agricultural College
      • Burlington, Vermont, Stati Uniti, 05401
        • Sospeso
        • University of Vermont Medical Center
    • Virginia
      • Richmond, Virginia, Stati Uniti, 23235
        • Reclutamento
        • VCU Massey Cancer Center at Stony Point
        • Contatto:
        • Investigatore principale:
          • Leopoldo J. Fernandez
      • Richmond, Virginia, Stati Uniti, 23298
        • Reclutamento
        • VCU Massey Comprehensive Cancer Center
        • Investigatore principale:
          • Leopoldo J. Fernandez
        • Contatto:
      • Roanoke, Virginia, Stati Uniti, 24033
        • Sospeso
        • Carilion Roanoke Memorial Hospital
      • Winchester, Virginia, Stati Uniti, 22601
        • Sospeso
        • Valley Health / Winchester Medical Center
    • Washington
      • Seattle, Washington, Stati Uniti, 98195
        • Sospeso
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Stati Uniti, 98109
        • Sospeso
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Sospeso
        • Northwest Wisconsin Cancer Center
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Sospeso
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Stati Uniti, 54843
        • Sospeso
        • Essentia Health-Hayward Clinic
      • Hayward, Wisconsin, Stati Uniti, 54843
        • Sospeso
        • Tamarack Health Hayward Medical Center
      • Marshfield, Wisconsin, Stati Uniti, 54449
      • Mukwonago, Wisconsin, Stati Uniti, 53149
        • Sospeso
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Stati Uniti, 53066
        • Sospeso
        • ProHealth Oconomowoc Memorial Hospital
      • Spooner, Wisconsin, Stati Uniti, 54801
        • Sospeso
        • Essentia Health-Spooner Clinic
      • Superior, Wisconsin, Stati Uniti, 54880
        • Sospeso
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Stati Uniti, 53188
        • Sospeso
        • ProHealth Waukesha Memorial Hospital
      • Waukesha, Wisconsin, Stati Uniti, 53188
        • Sospeso
        • UW Cancer Center at ProHealth Care

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential

  • Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date

  • Participants must not have a known history of a prior diagnosis of malabsorption syndrome

  • Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization

  • Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization

  • Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization

  • Participants must be ≥ 18 years old

  • Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization

  • Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization

  • Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:

    • Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
    • Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
    • Bromocriptine: Dose adjustments may be considered to account for absorption changes
    • Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
    • CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy

    • NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation

  • Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable

  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)

  • Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking

  • Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study

  • NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

  • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm I (lanreotide, distal pancreatectomy)

Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni

Undergo distal pancreatectomy

Given SC

Altri nomi:
  • Ipstil
  • Somatulina
  • Angiopeptina
  • BIM-23014
  • DC 13116
  • Dermopeptina
  • Somatuina
Comparatore placebo: Arm II (saline placebo, distal pancreatectomy)

Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni

Undergo distal pancreatectomy

Given SC

Altri nomi:
  • Cloruro di sodio 0,9%
  • Salino Normale
  • SOLUZIONE ISOTONICA DI CLORURO DI SODIO

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of postoperative pancreatic fistula (POPF)
Lasso di tempo: Up to 60 days after distal pancreatectomy

POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of biochemical leak (BL)
Lasso di tempo: Up to 60 days after distal pancreatectomy

BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Number of post-operation hospital days
Lasso di tempo: From the time of surgery up to 60 days after distal pancreatectomy

Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor.

From the time of surgery up to 60 days after distal pancreatectomy
Change in overall quality of life (QOL)
Lasso di tempo: At baseline and at 14 and 60 days after surgery

Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and at 14 and 60 days after surgery

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in pancreatic specific QOL
Lasso di tempo: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Change in health-related QOL
Lasso di tempo: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Delayed gastric emptying (DGE)
Lasso di tempo: Up to 60 days after distal pancreatectomy

DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Lasso di tempo: Up to 60 days after distal pancreatectomy

PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Time to initiation of adjuvant chemotherapy
Lasso di tempo: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy

Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test.

From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
Incidence of nausea and vomiting
Lasso di tempo: Up to 60 days after distal pancreatectomy

Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test.

Up to 60 days after distal pancreatectomy

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jonathan G Sham, SWOG Cancer Research Network

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 maggio 2025

Completamento primario (Stimato)

1 aprile 2029

Completamento dello studio (Stimato)

1 aprile 2029

Date di iscrizione allo studio

Primo inviato

29 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

29 gennaio 2025

Primo Inserito (Effettivo)

4 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • S2408
  • UG1CA189974 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2024-08361 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • SWOG-S2408 (Altro identificatore: DCP)
  • S2408 (Altro identificatore: SWOG)
  • S2408 (Altro identificatore: CTEP)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .